Standard Risk B-precursor Acute Lymphoblastic Leukemia. - AdisInsight
This phase III trial is assessing the efficacy, tolerability and quality-of-life effects of induction therapy with cytarabine + vincristine + dexamethasone +http://adisinsight.springer.com/trials/700003653
γ/δ T lymphocytes express CD40 ligand and induce isotype switching in B lymphocytes. | JEM
T cells expressing gamma/delta T cell receptors home to epithelial tissue and may play a role in immunity to infectious agents and foreign antigens. In an effort to understand the role of gamma/delta T cells in directing B cell responses, we investigated the capacity of human gamma/delta T cells to express CD40 ligand (CD40L) and to drive immunoglobulin (Ig) isotype switching in B cells. A multiple step purification procedure resulted in the recovery of highly pure populations of peripheral blood CD4-CD8- gamma/delta T cells. Neither CD40L surface expression nor CD40L mRNA were detected in unstimulated gamma/delta T cells. Stimulation with phorbol ester and ionomycin induced CD40L mRNA and surface CD40L expression by gamma/delta T ...http://jem.rupress.org/content/181/3/1239
"Regulation of gammadelta versus alphabeta T lymphocyte differentiation" by Heather J. Melichar, Kavitha Narayan et al.
alphabeta and gammadelta T cells originate from a common, multipotential precursor population in the thymus, but the molecular mechanisms regulating this lineage-fate decision are unknown. We have identified Sox13 as a gammadelta-specific gene in the immune system. Using Sox13 transgenic mice, we showed that this transcription factor promotes gammadelta T cell development while opposing alphabeta T cell differentiation. Conversely, mice deficient in Sox13 expression exhibited impaired development of gammadelta T cells but not alphabeta T cells. One mechanism of SOX13 function is the inhibition of signaling by the developmentally important Wnt/T cell factor (TCF) pathway. Our data thus reveal a dominant pathway regulating the developmental fate of these two lineages of T lymphocytes.http://escholarship.umassmed.edu/gsbs_sp/849/
gamma delta TCR Armenian Hamster anti-Mouse, Biotin, Clone: GL-3, eBioscience™ 100μg; Biotin gamma delta TCR Armenian Hamster...
gamma delta TCR Armenian Hamster anti-Mouse, Biotin, Clone: GL-3, eBioscience™ 100μg; Biotin gamma delta TCR Armenian Hamster anti-Mouse, Biotin, Clone: GL-3,...https://www.fishersci.co.uk/shop/products/gamma-delta-tcr-armenian-hamster-anti-mouse-biotin-clone-gl-3-ebioscience-1/15239839
gamma delta TCR Mouse anti-Human, PerCP-eFluor 710, Clone: B1.1, eBioscience™ 25 tests; PerCP-eFluor 710 gamma delta TCR Mouse...
gamma delta TCR Mouse anti-Human, PerCP-eFluor 710, Clone: B1.1, eBioscience™ 25 tests; PerCP-eFluor 710 gamma delta TCR Mouse anti-Human, PerCP-eFluor 710,...https://www.fishersci.co.uk/shop/products/gamma-delta-tcr-mouse-anti-human-percp-efluor-710-clone-b1-1-ebioscience/15509476
Gamma delta T cell - Wikipedia
Gamma delta T cells (γδ T cells) are T cells that have a distinctive T-cell receptor (TCR) on their surface. Most T cells are αβ (alpha beta) T cells with TCR composed of two glycoprotein chains called α (alpha) and β (beta) TCR chains. In contrast, gamma delta (γδ) T cells have a TCR that is made up of one γ (gamma) chain and one δ (delta) chain. This group of T cells is usually much less common than αβ T cells, but are at their highest abundance in the gut mucosa, within a population of lymphocytes known as intraepithelial lymphocytes (IELs). The antigenic molecules that activate gamma delta T cells are still largely unknown. However, γδ T cells are ...https://en.wikipedia.org/wiki/Gamma_delta_T_cell
Blinatumomab BLA to be Reviewed for Acute Lymphoblastic Leukemia - MPR
The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for blinatumomab for the treatment of adults with Philadelphia-negative (PH-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).http://www.empr.com/drugs-in-the-pipeline/blinatumomab-bla-to-be-reviewed-for-acute-lymphoblastic-leukemia/article/376556/
The Mechanisms of HOXA9-Mediated Oncogenic Transformation
Abstract: Hox genes encode a family of homeodomain-containing transcription factors that are critical for body plan specification and tissue morphogenesis during embryonic development. Hoxa9, in particular, is required for adult hematopoiesis in which it promotes stem cell renewal and expansion. Most importantly, Hoxa9 is commonly dysregulated in various types of acute leukemia, including acute myeloid leukemia (AML), and T- and B-precursor acute lymphoblastic leukemia (B-ALL and T-ALL). Together with its co-factor MEIS1, HOXA9 plays a causal role in driving leukemic transformation. Hoxa9 dysregulation is also linked to various types of solid tumors, and both gain and loss of function have been implicated in tumorigenesis. Despite its central role, the mechanism through which HOXA9 mediates oncogenic transformation remains poorly understood. Previous work in our lab found that in a HOXA9/MEIS1-driven AML cell line, HOXA9 ...https://deepblue.lib.umich.edu/handle/2027.42/138797
Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute...
The detection of minimal residual disease (MRD) after induction therapy and/or consolidation therapy is an independent prognostic factor for poor outcome of adult ALL. No standard treatments are available for patients with MRD-positive B-precursor ALL. Blinatumomab (MT103) is a bispecific single-chain antibody construct designed to link B cells and T cells resulting in T-cell activation and a cytotoxic T-cell response against CD19 expressing cells. The purpose of this study is to confirm whether the bispecific T-cell engager blinatumomab (MT103) is effective, safe and tolerable in the treatment of ALL patients with minimal residual disease.. Participants will receive up to four 4-week cycles of intravenous blinatumomab treatment followed by an infusion-free period of 14 days. A safety follow-up will be performed 30 days after the end of the last infusion and efficacy follow-ups will occur ...https://clinicaltrials.gov/ct2/show/NCT01207388?recr=Open&cond=%22Lymphatic+Diseases%22&rank=10
TRD Gene - GeneCards | TRD Protein | TRD Antibody
Complete information for TRD gene (Protein Coding), T-Cell Receptor Delta Locus, including: function, proteins, disorders, pathways, orthologs, and expression. GeneCards - The Human Gene Compendiumhttp://www.genecards.org/cgi-bin/carddisp.pl?gene=TRD
Anti-TCR gamma + TCR delta抗体[UC7-13D5] (Phycoerythrin)
亚美尼亚仓鼠单克隆抗体[UC7-13D5] to TCR gamma + TCR delta (Phycoerythrin)一抗数据表(ab25663).Abcam抗体、ELISA、激动剂拮抗剂、表观遗传试剂、蛋白多肽，使用效果保证，中国70%以上现货。http://www.abcam.cn/tcr-gamma-tcr-delta-antibody-uc7-13d5-phycoerythrin-ab25663.html
T Cell Lineage Commitment: Identity and Renunciation | The Journal of Immunology
Multipotent hematopoietic cells gain access to the T cell developmental pathway and then confirm that choice of fate by "burning their bridges" to other pathways. The process involves a continuing dialogue between the differentiating cell and the signals coming from its environment. The best understood of these signals are effects of Notch1 engagement with Delta ligands provided in the environment of the thymus, which are needed for T cell specification throughout the lineage-choice process and only become dispensable after T cell fate is confirmed (1-3). In vivo, expression of Notch ligand with supportive cytokines, such as IL-7 and Kit ligand, gives the thymus its T cell inductive activity (3). However, the cells that begin the T cell program initially have access to other options. These can be revealed if the cells are removed from the ...http://www.jimmunol.org/content/186/12/6649
Anti-TCR gamma + TCR delta antibody (Biotin) [UC7-13D5]
Anti-TCR gamma + TCR delta antibody conjugated to Biotin [UC7-13D5] validated for IP, IHC, FuncS, Flow Cyt and tested in Mouse. Referenced in 1 publication…http://www.abcam.com/tcr-gamma-tcr-delta-antibody-uc7-13d5-biotin-ab25209.html
Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous...
Acute NT was reported in 95 of 1,218 (7.8%) eligible patients treated on POG 9005. The incidence by regimen was regimen A, 46 of 543 patients (8.3%); regimen B, 13 of 354 patients (3.7%); and regimen C, 36 of 321 patients (11.2%) (P , .001). The majority of events were seizures and the median number of days to first occurrence of symptomatic NT after ITM or TIT was 10 to 11 days. Computed tomography (CT) or magnetic resonance imaging (MRI) evidence consistent with leukoencephalopathy (LE), with or without the presence of cerebral calcifications, was observed in 75% and 77.1 % of symptomatic patients treated on regimens A and C, respectively, but in only 15.4% of symptomatic patients treated on regimen B (P , .001). Factors associated with an increased incidence of NT included increased cumulative exposure with repeated i.v. MTX (regimens A and C v B), increased MTX-leucovorin (LCV) ratio (regimens A and C v B), and choice and timing of TIT therapy. The use of i.v. MP during intensification did ...http://imsdd.meb.uni-bonn.de/cgi-bin/mycite?ExtRef=MEDL/98246295/PMID/9586883
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic...
In the phase 2 extension cohort (efficacy phase) of the study, eligible participants less than 18 years were enrolled according to a two-stage design and received blinatumomab at the recommended dose level (5/15 μg/m²/day).. The study consisted of a screening period, a treatment period, and an End of Core Study visit 30 days after last dose of study medication. A treatment cycle consisted of a continuous intravenous (cIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks. Participants who achieved complete remission (CR) within 2 cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab. Instead of consolidation cycles with blinatumomab, participants could be withdrawn from blinatumomab treatment to receive chemotherapy or allogeneic HSCT as early as the first cycle, at the discretion of the investigator.. After the last treatment cycle and End of Core Study visit, all participants were followed for efficacy and survival for up to 24 ...https://clinicaltrials.gov/ct2/show/NCT01471782
NIOSHTIC-2 Publications Search - 20031974 - The role of gamma delta T cells in airway epithelial injury and bronchial...
BACKGROUND: Acute exposure to chlorine (Cl2) gas causes epithelial injury and airway dysfunction. gammadelta T cells are present in the mucosal surface of the airways and may contribute to the injury/repair response of the epithelium. METHODS: C57Bl/6J (wild type) and TCR-delta-/- mice exposed to Cl2 (400 ppm) for 5 minutes underwent measurements of airway responses to i.v. methacholine (MCh) at 1https://www.cdc.gov/niosh/nioshtic-2/20031974.html
KAKEN - Research Projects | Identification of the ligands of gamma delta T cells (KAKENHI-PROJECT-04454286)
Principal Investigator：SHIMADA Shinji, Project Period (FY)：1992 - 1994, Research Category：Grant-in-Aid for General Scientific Research (B), Research Field：Dermatologyhttps://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-04454286/
Case Reports - Reviews sub-cluster 14
The t(1;19)(q23;p13) translocation occurs in approximately 5% of B-precursor acute lymphoblastic leukemias (ALLs) occurring in children. Its presence has been associated with a poor prognosis, which may be overcome with more intensive therapy. Although leukemic cells from cases of t(1;19)-ALL frequently express cytoplasmic mu heavy chains, their complete antigenic profile ...http://www.biomedsearch.com/cluster/53/Case-Reports-Reviews/sub-14-p10.html
Genome Map [image] | EurekAlert! Science News
This is the genome map of [I]Zymoseptoria pseudotritici[/I]. The chromosomes have a mosaic structure of variable and non-variable segments. The individuals differ in the variable gene segments, which can contain genetic material of both parents. The identical regions, however, in each case retain only the genetic information from one of the parents.https://www.eurekalert.org/multimedia/pub/45202.php?from=216120
Rat Mono Anti-Mouse IgD delta chain (Unconjugated) 11-26 (ab99569) Protocols
There are no specific protocols for Rat monoclonal 11-26 Anti-Mouse IgD delta chain - Low endotoxin, Azide free (ab99569). Please download our general…http://www.abcam.com/rat-monoclonal-11-26-mouse-igd-delta-chain-low-endotoxin-azide-free-ab99569-protocols.html
The functioning and interrelationships of blood capillaries and lymphatics.
Abstract The structure and function of blood capillaries, as related to permeability, depends on tight, close and (in injured vessels) open junctional regions, small vesicles, vacu..https://www.omicsonline.org/references/the-functioning-and-interrelationships-of-blood-capillaries-and-lymphatics-979657.html
A 32-kD GTP-binding protein associated with the CD4-p56lck and CD8-p56lck T cell receptor complexes | Science
The guanosine triphosphate (GTP)-binding proteins include signal-transducing heterotrimeric G proteins (for example, Gs, Gi), smaller GTP-binding proteins that function in protein sorting, and the oncogenic protein p21ras. The T cell receptor complexes CD4-p56lck and CD8-p56lck were found to include a 32- to 33-kilodalton phosphoprotein (p32) that was recognized by an antiserum to a consensus GTP-binding region in G proteins. Immunoprecipitated CD4 and CD8 complexes bound GTP and hydrolyzed it to guanosine diphosphate (GDP). The p32 protein was covalently linked to [alpha-32P]GTP by ultraviolet photoaffinity labeling. These results demonstrate an interaction between T cell receptor complexes and an intracellular GTP-binding protein. ...http://science.sciencemag.org/content/254/5030/439
Atomic structure of a T cell receptor binding to a peptide-MHC complex (1996) | British Society for Immunology
Seeing is believing. This is a truism in immunology just as it is in many spheres of science. The story of the first X-ray crystallography image of T-cells binding to the antigenshttps://www.immunology.org/atomic-structure-t-cell-receptor-binding-peptidemhc-complex-1996
Identification of T cell receptor recognition residues for a viral peptide presented by HLA B27. - The Kennedy Institute of...
The fine specificity of T cell recognition of peptide analogues of the influenza nucleoprotein epitope, NP 383-391 SRYWAIRTR, was studied using HLA B27-restricted influenza-specific cytotoxic T cell (CTL) clones, of defined T cell receptor (TcR) usage, derived from unrelated individuals following natural infection. Even conservative amino acid substitutions of the peptide residues P4, P7 and P8 influenced CTL recognition. These side chains are probably directly contacted by the TcR. CTL clones which used the TcR V alpha 14 gene segment (but not those using TcR V alpha 12) were also sensitive to P1 substitutions, suggesting that the TcR alpha chain of these clones lies over the N terminus of bound peptide, and that the 'footprint' of certain TcR can span all exposed residues of a peptide bound to a major histocompatibility complex class I molecule. These results, taken together with previous ...https://www.kennedy.ox.ac.uk/publications/35613
Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies | Haematologica
To investigate whether the sub-optimal cell-surface expression of the HA-1-TCR after gene transfer was due to intrinsic properties of the TCR, we determined the HA-1-TCR cell-surface expression of five different parental HA-1-specific T-cell clones derived from different individuals. As demonstrated in Figure 1A, the HA-1-specific T-cell clones expressed significant lower levels of TCR-CD3 complexes at the cell-surface compared to HA-2-15 or CMVA2-specific18 T-cell clones. The HA-1 T-cell clones, however, stained with similar intensity with their respective tetramer to other T-cell clones (Figure 1B), and were fully functional T cells (data not shown). To exclude the possibility that the low TCR expression was due to lower transcriptional activity, TCRα and β mRNA levels were determined, and no significant differences in HA-1-TCRα or β mRNA ...http://www.haematologica.org/content/96/3/477